253 related articles for article (PubMed ID: 35105856)
21. Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing.
Patnaik MM; Lasho TL; Finke CM; Hanson CA; King RL; Ketterling RP; Gangat N; Tefferi A
Am J Hematol; 2016 May; 91(5):492-8. PubMed ID: 26874914
[TBL] [Abstract][Full Text] [Related]
22. Refractory anemia with ring sideroblasts.
Malcovati L; Cazzola M
Best Pract Res Clin Haematol; 2013 Dec; 26(4):377-85. PubMed ID: 24507814
[TBL] [Abstract][Full Text] [Related]
23. Many faces of SF3B1-mutated myeloid neoplasms: concurrent mutational profiles contribute to the diverse clinical and morphologic features.
Aqil B; Sukhanova M; Behdad A; Jennings L; Lu X; Chen Q; Chen YH; Gao J
Hum Pathol; 2022 Nov; 129():81-89. PubMed ID: 36087739
[TBL] [Abstract][Full Text] [Related]
24. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Patnaik MM; Lasho TL
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):450-459. PubMed ID: 33275756
[TBL] [Abstract][Full Text] [Related]
25. JAK2 exon 12 mutation in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Not an exclusive mutation to polycythaemia vera.
Inano T; Araki M; Morishita S; Imai M; Yasuda H; Nitta H; Ito M; Edahiro Y; Ochiai T; Misawa K; Fukuda Y; Ohsaka A; Komatsu N
Br J Haematol; 2019 Oct; 187(1):e27-e31. PubMed ID: 31418453
[No Abstract] [Full Text] [Related]
26. Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations.
Liu YC; Illar GM; Bailey NG
J Clin Pathol; 2020 Nov; 73(11):728-736. PubMed ID: 32217616
[TBL] [Abstract][Full Text] [Related]
27. Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a "catch-all" term?
Shallis RM; Zeidan AM
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101132. PubMed ID: 32460977
[TBL] [Abstract][Full Text] [Related]
28. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation.
Szpurka H; Tiu R; Murugesan G; Aboudola S; Hsi ED; Theil KS; Sekeres MA; Maciejewski JP
Blood; 2006 Oct; 108(7):2173-81. PubMed ID: 16741247
[TBL] [Abstract][Full Text] [Related]
29. Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).
Antelo G; Mangaonkar AA; Coltro G; Buradkar A; Lasho TL; Finke C; Carr R; Binder M; Gangat N; Al-Kali A; Elliott MA; King RL; Howard M; Melody ME; Hogan W; Litzow MR; Tefferi A; Fernandez-Zapico ME; Komrokji R; Patnaik MM
Br J Haematol; 2020 May; 189(3):e104-e108. PubMed ID: 32128785
[No Abstract] [Full Text] [Related]
30. Refractory anemia with ring sideroblasts associated with marked thrombocytosis: a mixed group exhibiting a spectrum of morphologic findings.
Gurevich I; Luthra R; Konoplev SN; Yin CC; Medeiros LJ; Lin P
Am J Clin Pathol; 2011 Mar; 135(3):398-403. PubMed ID: 21350094
[TBL] [Abstract][Full Text] [Related]
31. Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms.
Palomo L; Meggendorfer M; Hutter S; Twardziok S; Ademà V; Fuhrmann I; Fuster-Tormo F; Xicoy B; Zamora L; Acha P; Kerr CM; Kern W; Maciejewski JP; Solé F; Haferlach C; Haferlach T
Blood; 2020 Oct; 136(16):1851-1862. PubMed ID: 32573691
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of SF3B1 mutations in Korean patients with myelodysplastic syndromes and myelodysplasia/myeloproliferative neoplasms with ring sideroblasts.
Seo JY; Lee KO; Kim SH; Kim K; Jung CW; Jang JH; Kim HJ
Ann Hematol; 2014 Apr; 93(4):603-8. PubMed ID: 24141330
[TBL] [Abstract][Full Text] [Related]
33. Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts.
Chen Z; Wang SA; Goswami M; Tang G; Routbort MJ; Patel KP; Luthra R; Medeiros LJ; Ok CY
Leuk Res; 2019 Nov; 86():106227. PubMed ID: 31557598
[TBL] [Abstract][Full Text] [Related]
34. Refractory anemia with ringed sideroblasts and thrombocytosis without JAK2 V617F mutation: report of three cases.
Tatic A; Vasilică M; Coliţă A; Vasilache D; Dobrea C; Jardan C; Găman AM; Crişan AM; Coliţă D; Coriu D
Rom J Morphol Embryol; 2013; 54(4):1177-82. PubMed ID: 24399021
[TBL] [Abstract][Full Text] [Related]
35. JAK2/CALR/SF3B1 triple-mutated myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis evolving to myelofibrosis and SF3B1 single-mutated acute myeloid leukemia: Evidence of a pre-JAK2 clone.
Yasuda H; Morishita S; Mori Y; Tsukune Y; Inano T; Harada S; Komatsu N
Leuk Res; 2021 Jan; 100():106496. PubMed ID: 33373831
[No Abstract] [Full Text] [Related]
36. Myelodysplastic/myeloproliferative neoplasms.
Hyjek E; Vardiman JW
Semin Diagn Pathol; 2011 Nov; 28(4):283-97. PubMed ID: 22195406
[TBL] [Abstract][Full Text] [Related]
37. Challenges in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN).
Smith BN; Savona M; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):1-8. PubMed ID: 30555034
[TBL] [Abstract][Full Text] [Related]
38. Bone marrow ring sideroblasts in hematological diseases: an analysis of consecutive 1300 samples in a single institution.
Hayama K; Abe Y; Kamata H; Okina S; Murakami Y; Kanoh Y; Suzuki T
Int J Hematol; 2022 Apr; 115(4):508-514. PubMed ID: 35064465
[TBL] [Abstract][Full Text] [Related]
39. Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms.
Gerke MB; Christodoulou I; Karantanos T
Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568631
[TBL] [Abstract][Full Text] [Related]
40. 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
Hu Z; Hu S; Ji C; Tang Z; Thakral B; Loghavi S; Medeiros LJ; Wang W
Leuk Res; 2018 Feb; 65():25-28. PubMed ID: 29288910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]